Navigation Links
Access Pharmaceuticals Provides Update on MuGard Commercial Activities
Date:5/17/2011

DALLAS and NEW YORK, May 17, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that it had made significant progress with the commercial introduction of MuGard in the radiation oncology and medical oncology communities.  MuGard is a novel, ready-to-use mucoadhesive oral wound rinse and coating that has been shown to be very effective in the management of oral mucositis, a debilitating side effect of many anticancer treatments.  Access provided the following information related to its ongoing commercialization efforts:

  • Salesforce Management:  At the end of 2010, Access commenced training of third-party MuGard representatives on the product, the oral mucositis condition and sales strategy.  These reps initiated a broad-scale marketing push that will continue throughout 2011.  While greater than 90 reps have received initial MuGard training, efforts to identify and train additional representatives in uncovered or under-resourced geographic areas will also remain a focus throughout the year.

  • MuGard Prescriptions Ramping:  MuGard prescriptions have been ramping consistently for the last several weeks, starting from 10 prescriptions per week and growing to greater than 75 prescriptions per week.  Over 200 doctors to date have prescribed MuGard for their patients and over 80% of these doctors are reoccurring prescribers.  Access believes it has the right team and resources in place to continue ramping prescriptions throughout the year.

  • Reimbursement Activities:  The Company has placed a significant emphasis on its sampling and marketing efforts to build demand, grow oncologist awa
    '/>"/>

    • SOURCE Access Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. CVS Caremark to Pilot Electronic Prior Authorization to Help Speed Patient Access to Prescription Medication
    2. Arstasis Launches New AXERA™ Access Device in the U.S.
    3. SCAI Releases First Report on Transradial Access for Angioplasty and Stenting
    4. New NCPA Study: Medicaid Pharmacy Modernization Could Save States Billions Without Limiting Access
    5. HistoRx Announces Launch of New Research Services: AQUAPrep™ and Access AQUA® Services Now Available
    6. Otto Kaiser Memorial Hospital Turns to Prognosis ChartAccess® Comprehensive EHR to Meet Organizational Aspirations
    7. Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress
    8. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
    9. Thorne Research and Integrative Health Resources Establish Joint Venture to Provide Full Range of Services in Practice Development, Patient and Clinician Education, and Access to Nutritional Supplements in Integrative Medicine
    10. Seymour Hospital Seeks to Meet Meaningful Use Requirements With Prognosis ChartAccess® Comprehensive EHR
    11. New Affiliation Between MinuteClinic and Advocate Health Care Increases Access to Medical Services in Chicagoland
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/18/2013)... 18, 2013 Today, Wall Street Reports ... GILD ), Health Management Associates Inc. (NYSE: ... ISIS Pharmaceuticals Inc. (NASDAQ: ISIS ), and Trius ... free of charge - including full price targets, industry analysis ... Gilead Sciences, Inc. Research Report On June 7, ...
    (Date:6/18/2013)... SALT LAKE CITY , June 18, 2013 ... registry-based informatics products for healthcare and life sciences ... U.S. General Services Administration (GSA) IT Schedule 70 ... is now certified to provide innovative IT solutions ... levels. In accordance with this contract, Remedy has ...
    (Date:6/18/2013)... 2013 Apama Medical, a privately held ... next-generation atrial fibrillation technologies, today announced the issuance ... Patent and Trademark Office (USPTO), titled "Low Profile ... for use on expandable structures such as balloons ... "We are grateful to the NSF ...
    Breaking Medicine Technology:Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4
    ... announced that data,presented recently at the 17th Annual ... that the Genous Bio-engineered R,stent has better outcomes ... Federico Piscione, M.D., the study,s principal,investigator and a ... of Cardiology, Department of Clinical Medicine and Cardiovascular,Sciences, ...
    ... Results are basis for CTI,s Marketing Authorization Application currently ... under ... Inc. (CTI),(Nasdaq: CTIC ; MTA) today announced the publication of ... gemcitabine or vinorelbine for the treatment of PS 2,(performance status 2) ...
    Cached Medicine Technology:Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5
    (Date:6/18/2013)... June 18, 2013 As obesity rates sky ... need for surgical equipment during childbirth comes as no shock. ... within the mother when she is unable to do so ... are associated with higher rates of complication for both the ... harmful to the mother and child, forceps births add to ...
    (Date:6/18/2013)... WA (PRWEB) June 18, 2013 SEATTLE, ... Townsend Farms of Fairview, Oregon, claiming he fell ill ... frozen berry and pomegranate seed blend. The complaint ... 13-2-05597-8) by Marler Clark, the Seattle-based law firm that ... .[1] , According to the complaint, Brian Brothers consumed ...
    (Date:6/18/2013)... The Drug Delivery Partnering Terms and Agreements ... drug delivery partnering deals and agreements entered into by ... provides a detailed understanding and analysis of how and ... of deals are discovery or development stage whereby the ... license the license drug delivery technology. These deals tend ...
    (Date:6/18/2013)... The Temp1000IS temperature data logger ... can be used to automatically record temperatures between -20 ... Temp1000IS comes with the serial number and device name ... (sold separately) docking station and can be placed directly ... removal of end-caps to download data. The small size ...
    (Date:6/18/2013)... Parker Waichman LLP , a ... victims injured by defective medical devices, reports that the ... bone graft products are now available. Published this week ... two studies serve up two key findings: There is ... and the traditional bone graft; and there is “substantial ...
    Breaking Medicine News(10 mins):Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3
    ... Reinberg HealthDay Reporter , WEDNESDAY, May 25 ... a "polypill," appears to cut users, odds for heart ... study finds. The pill combines two blood pressure-lowering ... designed to make all these heart-protecting drugs easy to ...
    ... 25, 2011) The cost of cancer care is threatening ... but at staggering costs. This coupled with aging baby boomers ... billion annually on cancer care by the year 2020. This ... maintain or improve the quality of care while saving money ...
    ... CA (May 26, 2011) Precision tinted lenses have ... poor readers, and are increasingly used for migraine sufferers, ... been unclear. Now research published in the journal ... imaging (fMRI) for the first time to suggest a ...
    ... NY, May 26, 2011Young adults ages 19-29 are struggling to ... other age group, demonstrating the need for Affordable Care Act ... and make it more affordable, according to a new Commonwealth ... of young adults couldn,t afford the care they needed, meaning ...
    ... 2011 UT Southwestern Medical Center researchers are engaging the ... component in red wine and grapes could help reduce the ... recruit about two dozen professional boxers to take the neuroprotective ... damage to the brain after impact and helps restore subtle ...
    ... bats and dolphins echolocate, emitting bursts of sounds and then ... What is less well-known is that people can echolocate too. ... make clicks with their mouths and to use the returning ... these individuals are so adept at echolocation that they can ...
    Cached Medicine News:Health News:Daily Four-Drug Combo Pill Halves Heart Disease Risk: Study 2Health News:Daily Four-Drug Combo Pill Halves Heart Disease Risk: Study 3Health News:Oncologists hold key to curbing cancer costs 2Health News:Oncologists hold key to curbing cancer costs 3Health News:Tinted specs offer real migraine relief, says fMRI study 2Health News:Tinted specs offer real migraine relief, says fMRI study 3Health News:Health reform essential to young adults: Nearly half can't afford needed health care 2Health News:Health reform essential to young adults: Nearly half can't afford needed health care 3Health News:Health reform essential to young adults: Nearly half can't afford needed health care 4Health News:Researchers evaluate red wine compound for treating concussions in pro boxers 2Health News:'I can hear a building over there' 2
    The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
    The BD Vacutainer® One Use Holder is a quality, low-cost single use holder that can help customers comply with OSHA regulations (Safety and Health Information Bulletin 10-15-03)...
    The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
    Inquire...
    Medicine Products: